AmpVision: Biomedical Device startup
Target: Dry Age-related Macular Degeneration (no current treatments)
Market: 170M patients worldwide
Competition: Drugs under development (2-5 years from market)

Technology: Ocular implant, outperforms drugs by 40x
Edge: Low production cost, lower regulatory hurdles, quicker to market
Science: preclinical biocompatibility and efficacy data
IP: Patent issued in Dec 2019, several pending